Torres O.
85
Coauthors
6
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2001 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2010 | 1 |
| 2022 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 5 |
| Farmacología | 3 |
| Inmunología | 3 |
| Ensayo clínico | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Farmacología y terapéutica | 5 |
| Enfermedades | 5 |
| Medicina y salud | 2 |
| Problemas sociales y servicios a grupos | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 6 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Tania Crombet | 6 |
| Lage Davila A. | 4 |
| Iznaga N. | 4 |
| Pérez R. | 3 |
| Ramos M. | 3 |
| Leonard I. | 2 |
| Torres F. | 2 |
| Neninger Vinageras E. | 2 |
| Fernández E. | 2 |
| Figueredo R. | 2 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Phase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor
ArticleAbstract: Ior egf/r3 a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR)Palabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, Phase I clinical trial, Tyrosine kinase inhibitorsAutores:Catalaá M., Fernández E., Iznaga N., Neninger Vinageras E., Peérez R., Ramos M., Rodríguez N., Tania Crombet, Torres O.Fuentes:scopusPharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer
ArticleAbstract: Epidermal growth factor receptor (EGFR) overexpression has been detected in many tumors of epitheliaPalabras claves:Epidermal growth factor receptor, Monoclonal antibody, Phase I clinical trialAutores:Catala M., Iznaga N., Lage Davila A., Neninger Vinageras E., Perera A., Pérez R., Solano M., Tania Crombet, Torres F., Torres L., Torres O.Fuentes:scopusShort communication: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study
ArticleAbstract: High levels of growth factors and their receptors have been demonstrated in human tumors. Gliomas anPalabras claves:Autores:Figueredo R., Iznaga N., Lage Davila A., Menéndez A., Pérez R., Ramos M., Rodríguez V., Stevenson A., Tania Crombet, Torres F., Torres O., Veitía I.Fuentes:scopusUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
ArticleAbstract: Purpose: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor rPalabras claves:Autores:Alvarez D., Cruz T., Del Castillo R., Fernández E., Figueredo R., Iznaga-Escobar N., Koropatnick J., Lage Davila A., Leonard I., Mon R., Osorio M., Pérez R., Ramos M., Renginfo E., Roca C., Tania Crombet, Torres O.Fuentes:scopusMulticentre oncology clinical trials in primary health care in Cuba: evaluation of programme implementation in Villa Clara Province, 2010–2020
ArticleAbstract: Background: The Center of Molecular Immunology of Cuba has developed a programme for the conductingPalabras claves:clinical trials, General practitioners, immunotherapy, neoplasms, Oncology, Primary Health Care, primary healthcareAutores:Artiles M., Cepeda M., Crespo J.C., de la Barca N.d.C., González A., Granela M.C., Lage Davila A., Lorenzo G., Marrero R., Méndez R., Nieto L., Norvel M., Ortiz R.A., Rodríguez M., Sánchez L., Tania Crombet, Toledo E., Torres O.Fuentes:scopus